Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.52 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5709362 | 0.90 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL2481230 | 0.90 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL6196126 | 0.86 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL6196129 | 0.86 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL18082335 | 0.85 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2EPHX2NR1H4 | |
| SCHEMBL15090036 | 0.84 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2EPHX2NR1H4 | |
| SCHEMBL16373032 | 0.84 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2EPHX2NR1H4 | |
| SCHEMBL15087731 | 0.84 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2EPHX2NR1H4 | |
| SCHEMBL3057455 | 0.84 | TACR1 (0.60) | NPC1RAB9ASMN1; SMN2MAPTTP53 | |
| SCHEMBL3641034 | 0.84 | FFAR1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | DEPARTMENT OF VETERANS AFFAIRS | 2009-02-12 | — | — | US | disclosed |
| WO-2008151184-A1 | BENZAMIDE MGLUR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | VANDERBILT UNIVERSITY (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042855-A1 | BENZAMIDE mGluR5 POSITIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING SAME | GRM5, GRIK5, GRM3 | NPC1 2371/4885RAB9A 3119/4885SMN1; SMN2 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.